150 related articles for article (PubMed ID: 38256182)
1. Pharmacokinetic and Pharmacodynamic Analysis of the Oxacephem Antibiotic Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales from Dogs.
Kusumoto M; Jitsuiki M; Motegi T; Harada K
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256182
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
3. In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales.
Iio K; Hagiya H; Higashionna T; Otsuka F
New Microbiol; 2024 Jan; 46(4):348-353. PubMed ID: 38252045
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of cephamycins against multiple extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae isolates from dogs and cats.
Kusumoto M; Kanao Y; Narita H; Jitsuiki M; Iyori K; Tsunoi M; Tsuyuki Y; Torii K; Harada K
J Vet Med Sci; 2023 Jun; 85(6):653-656. PubMed ID: 37150609
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic analysis of cefmetazole against extended-spectrum β-lactamase-producing Enterobacteriaceae in dogs using Monte Carlo Simulation.
Kusumoto M; Motegi T; Uno H; Yokono M; Harada K
Front Vet Sci; 2023; 10():1270137. PubMed ID: 37841458
[TBL] [Abstract][Full Text] [Related]
6. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea.
Jung Y; Lee SS; Song W; Kim HS; Uh Y
Diagn Microbiol Infect Dis; 2019 May; 94(1):88-92. PubMed ID: 30658867
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
9.
Yamashiro H; Kasamatsu Y; Anan N; Takemura M; Yamano Y
Antimicrob Agents Chemother; 2023 Sep; 67(9):e0025823. PubMed ID: 37610203
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of extended-spectrum beta-lactamase-producing
Siriphap A; Kitti T; Khuekankaew A; Boonlao C; Thephinlap C; Thepmalee C; Suwannasom N; Khoothiam K
Front Cell Infect Microbiol; 2022; 12():955774. PubMed ID: 36004324
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model.
Tashiro S; Hayashi M; Takemura W; Igarashi Y; Liu X; Mizukami Y; Kojima N; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K
Pharm Res; 2021 Jan; 38(1):27-35. PubMed ID: 33404990
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Molecular Findings of Infections Caused by Extended-Spectrum β-Lactamase-Producing
Szymankiewicz M; Stefaniuk E; Baraniak A; Nowikiewicz T
Microb Drug Resist; 2021 Nov; 27(11):1470-1481. PubMed ID: 34264754
[TBL] [Abstract][Full Text] [Related]
13.
Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
[TBL] [Abstract][Full Text] [Related]
14. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
[TBL] [Abstract][Full Text] [Related]
15. A multicentre study to determine the
Yap PSX; Chong CW; Ponnampalavanar S; Ramli R; Harun A; Tengku Jamaluddin TZM; Ahmed Khan A; Ngoi ST; Lee YQ; Lau MY; Tan SC; Kong ZX; Woon JJ; Mak ST; Abdul Jabar K; Karunakaran R; Ismail Z; Salleh SA; Md Noor SS; Masri SN; Mohd Taib N; Jasni AS; Tee LH; Leong KC; Lim VKE; Abu Bakar S; Teh CSJ
PeerJ; 2023; 11():e16393. PubMed ID: 38047021
[TBL] [Abstract][Full Text] [Related]
16. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.
Jones CH; Tuckman M; Keeney D; Ruzin A; Bradford PA
Antimicrob Agents Chemother; 2009 Feb; 53(2):465-75. PubMed ID: 19015360
[TBL] [Abstract][Full Text] [Related]
17. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y
BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
Lee CH; Su LH; Tang YF; Liu JW
J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
[TBL] [Abstract][Full Text] [Related]
20. High burden of ESBL- producing Klebsiella spp., Proteus mirabilis, Enterobacter cloacae and Pseudomonas aeruginosa in diagnosed cases of urinary tract infection in a Nigerian Teaching Hospital.
Adekanmbi AO; Akinlabi OC; Usidamen S; Olaposi AV; Olaniyan AB
Acta Microbiol Immunol Hung; 2022 Jun; 69(2):127-134. PubMed ID: 35895567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
